{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:42:04Z","timestamp":1790080924700,"version":"4.0.1"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Idelalisib is the first orally active selective phosphatidylinositol 3-kinase delta inhibitor approved by Food and Drug Administration and European Medicines Agency in 2014 for the treatment of several types of blood cancer. Idelalisib is widely used as a monotherapy or in combination with rituximab, bendamustine, or ofatumumab with a significant efficacy. However, idelalisib has shown increased risk of infection and a higher frequency of serious adverse events. It may be useful to determine idelalisib concentration in human plasma to adjust dose and to manage adverse effects in clinical practice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>After a single-step protein precipitation of plasma samples, the chromatographic separation was performed using an ultra-high performance liquid chromatography system coupled with mass tandem spectrometry in a negative ionization mode using isotope-labeled internal standard. This method was validated by studies of its linearity, accuracy, imprecision, limit of quantification, recovery, matrix effect, selectivity, and stability.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The quantification method was linear from 10 to 2500 ng\/mL with a 5 ng\/mL lower limit of quantification that encompasses the clinical range of drug concentration. The intraday and interday imprecisions were below 8.1% and 11.4%, respectively. The recoveries and matrix effect of idelalisib were 85.6% \u00b1 1.2% and 95.7% \u00b1 3.0%, respectively, which are consistent, precise, and reproducible (coefficient of variation % &lt; 15%). Peak plasma concentration and trough plasma concentration ranges of idelalisib reached 1591\u20131937 ng\/mL and 256.3\u2013303.3 ng\/mL, respectively, in 3 follicular lymphoma patients treated with idelalisib 150 mg twice a day.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>A robust and sensitive liquid chromatography\u2013tandem mass spectrometry method was developed and validated to quantify idelalisib concentration in human plasma. This method was effectively applied to 3 follicular lymphoma patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000488","type":"journal-article","created":{"date-parts":[[2018,3,11]],"date-time":"2018-03-11T23:27:19Z","timestamp":1520810839000},"page":"237-244","source":"Crossref","is-referenced-by-count":12,"title":["Quantification of Idelalisib in Human Plasma by Ultra-Performance Liquid Chromatography Coupled to Mass Spectrometry in Negative Ionization Mode"],"prefix":"10.1097","volume":"40","author":[{"given":"Huu H.","family":"Huynh","sequence":"first","affiliation":[{"name":"Pharmacology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Roessle","sequence":"additional","affiliation":[{"name":"Pharmacology, and"},{"name":"Pharmacy, AP-HP, H\u00f4pital Saint-Louis;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Sauvageon","sequence":"additional","affiliation":[{"name":"Pharmacology, and"},{"name":"Pharmacy, AP-HP, H\u00f4pital Saint-Louis;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Pl\u00e9","sequence":"additional","affiliation":[{"name":"Pharmacology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Madelaine","sequence":"additional","affiliation":[{"name":"Pharmacy, AP-HP, H\u00f4pital Saint-Louis;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"Hemato-oncology Department, AP-HP, H\u00f4pital Saint-Louis, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Mourah","sequence":"additional","affiliation":[{"name":"Pharmacology, and"},{"name":"INSERM UMR_S976, Saint-Louis Hospital, Universit\u00e9 Paris-Diderot, Sorbonne Paris Cit\u00e9, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauriane","family":"Goldwirt","sequence":"additional","affiliation":[{"name":"Pharmacology, and"},{"name":"INSERM UMR_S976, Saint-Louis Hospital, Universit\u00e9 Paris-Diderot, Sorbonne Paris Cit\u00e9, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230928","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"R2-20230928","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"key":"R3-20230928","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1586\/17474086.2015.1071663","article-title":"Idelalisib for relapsed\/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes","volume":"8","author":"Davies","year":"2015","journal-title":"Expert Rev Hematol."},{"key":"R4-20230928","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s40265-014-0285-6","article-title":"Idelalisib: first global approval","volume":"74","author":"Markham","year":"2014","journal-title":"Drugs"},{"key":"R5-20230928","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Zelenetz","year":"2017","journal-title":"Lancet Oncol."},{"key":"R6-20230928","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/S2352-3026(17)30019-4","article-title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","volume":"4","author":"Jones","year":"2017","journal-title":"Lancet Haematol."},{"key":"R7-20230928","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1078155216653705","article-title":"Drug interaction between idelalisib and diazepam resulting in altered mental status and respiratory failure","volume":"23","author":"Bossaer","year":"2016","journal-title":"J Oncol Pharm Pract."},{"key":"R8-20230928","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40262-015-0304-0","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of idelalisib","volume":"55","author":"Ramanathan","year":"2016","journal-title":"Clin Pharmacokinet."},{"key":"R9-20230928","first-page":"4998","article-title":"Methode development and validation for the estimation of idelalisib in rabbit plasma by HPLC","volume":"7","author":"Suneetha","year":"2016","journal-title":"Int J Pharm Sci Res."},{"key":"R10-20230928","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jchromb.2014.01.001","article-title":"Simultaneous quantification of idelalisib, fludarabine and lenalidomide in rat plasma by using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass spectrometry","volume":"949\u2013950","author":"Veeraraghavan","year":"2014","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R11-20230928","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jchromb.2004.04.039","article-title":"Confirmatory analysis for drugs of abuse in plasma and urine by high-performance liquid chromatography-tandem mass spectrometry with respect to criteria for compound identification","volume":"811","author":"Maralikova","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R13-20230928","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.ejca.2014.04.015","article-title":"Review of therapeutic drug monitoring of anticancer drugs part two\u2014targeted therapies","volume":"50","author":"Widmer","year":"2014","journal-title":"Eur J Cancer"},{"key":"R14-20230928","article-title":"Guidance for industry\u2014analytical procedures and methods validation for drugs and biologics","year":"2015","journal-title":"Food Drug Adm."},{"key":"R15-20230928","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1023\/A:1007669411738","article-title":"Bioanalytical method validation\u2013a revisit with a decade of progress","volume":"17","author":"Shah","year":"2000","journal-title":"Pharm Res."},{"key":"R16-20230928","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal Chem."},{"key":"R17-20230928","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/1044-0305(93)85019-T","article-title":"Negative ion formation in electrospray mass spectrometry","volume":"4","author":"Straub","year":"1993","journal-title":"J Am Soc Mass Spectrom."},{"key":"R18-20230928","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1021\/ac0351670","article-title":"Favorable effects of weak acids on negative-ion electrospray ionization mass spectrometry","volume":"76","author":"Wu","year":"2004","journal-title":"Anal Chem."},{"key":"R19-20230928","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jchromb.2013.01.037","article-title":"Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC\/MS\/MS","volume":"926","author":"Andriamanana","year":"2013","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R20-20230928","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/FTD.0000000000000357","article-title":"Development and validation of a simultaneous quantification method of 14 tyrosine kinase inhibitors in human plasma using LC-MS\/MS","volume":"39","author":"Huynh","year":"2017","journal-title":"Ther Drug Monit."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201804000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T01:06:46Z","timestamp":1695863206000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201804000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000488","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}